LILRB1 Antibody / LIR-1

Overview

Leukocyte immunoglobulin-like receptors (LIRs) are members of the immunoglobulin superfamily of glycoproteins and are predominantly expressed by monocytes, B cells, dendritic cells, natural killer (NK) cells, peripheral blood leukocytes and tissues such as placenta, lung and liver. Immunoglobulin-like transcript 2 (ILT-2), also known as CD85 or MIR7, is a 650 amino acid glycoprotein that contains a 23 amino acid signal peptide, 4 extracellular C2-type IGSF domains and 4 intracellular ITIM motifs. ILT-2 can bind major histocompatability (MHC) class I molecules and inhibit cell termination by natural killer (NK) and T cells, and inhibit Ca2+ mobilization in myeloid cells triggered through the B cell antigen receptor and histocompatibility leukocyte antigens (HLA)-DR. ILT-2 contains four putative cytoplasmic tyrosine-based inhibitory motifs and upon tyrosine phosphorylation, associates with the tyrosine phosphatase SHP-1.

This anti-LIR-1 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone VMP55, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: LIR-1
• Format: Purified
• Localization: Cell surface
• Species reactivity: Human
• Applications (listed): IP, WB, FACS
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone VMP55, Mouse IgG1, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

LIR-1 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling LIR-1 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link LIR-1 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• IP
• WB
• FACS

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.